John Maher
Chief Scientific Officer
Leucid Bio
Leucid Bio develops next-generation CAR-T therapies using its proprietary Lateral CAR platform, which enhances T-cell potency and durability by mimicking the natural distribution of signaling domains in immune receptors. This technology targets refractory cancers, providing improved treatment outcomes with reduced toxicity compared to traditional CAR-T therapies.
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$8.9MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Traditional CAR-T therapies have shown limited efficacy in solid tumors due to challenges such as poor T-cell infiltration, immunosuppressive tumor microenvironments, and off-target toxicities. Existing CAR-T designs may not fully replicate the natural signaling mechanisms of immune receptors, potentially limiting T-cell potency and durability.
Solution
Leucid Bio is developing next-generation CAR-T therapies using its proprietary Lateral CAR platform to enhance T-cell function and improve outcomes in refractory cancers. The Lateral CAR design mimics the natural distribution of signaling domains in immune receptors, leading to enhanced T-cell potency, improved tumor targeting, and a more persistent, long-term response. Leucid's lead asset, LEU011, targets NKG2D ligands, which are expressed on a broad range of solid tumors and hematological malignancies, offering a potential treatment for multiple cancer indications. The company is also developing novel manufacturing platforms to improve the scalability and speed of CAR-T production, relying on a simple blood draw.
Target Audience
The primary target audience includes patients with refractory solid tumors and hematological malignancies who have limited treatment options, as well as clinicians seeking more effective and durable CAR-T therapies.
Features
- Lateral CAR platform that enhances T-cell potency and generates a persistent long-term response with reduced toxicity
- LEU011, a lead asset targeting NKG2D ligands expressed on over 80% of human tumor cells
- LEU011 engineered to co-express the chemokine receptor, CXCR2, to enhance cell trafficking and tumor infiltration
- Novel manufacturing platforms for rapid and scalable CAR-T production from a simple blood draw
- T2, gd T-cells for off-the-shelf cell therapy
- T4 Immunotherapy, a pan-ErbB targeted autologous CAR T-cell product for patients with otherwise untreatable head and neck cancer